DXR NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Daxor Corporation · Healthcare · Medical Instruments & Supplies

Open interactive chart View report data
Latest close 10.50 USD
0.5% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -4.7% below the Trend Line and sits at 31.3% of its 52-week range. The latest completed week returned 0.5%, after a 1.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is inexpensive relative to peers. The latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal.

Setup score 37 out of 100
Latest Close 10.50 USD 31 Jul 2026
1W Return 0.5% latest completed week
4W Return 1.2% short-term follow-through
12W Return 5.5% quarterly tape
Trend Breadth 53.8% 28 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.5% Latest completed week; four-week move 1.2%. Indicator stack 30/100 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 56/100 44 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -4.7% below the Trend Line and sits at 31.3% of its 52-week range. The latest completed week returned 0.5%, after a 1.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1012-week average 0.07

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.10Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 1.2% over four weeks, 5.5% over 12 weeks, and 11.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W0.5%
4W1.2%
12W5.5%
26W-21.0%
52W11.1%
Active trend streak0 weeks
Active weeks in one year28
Trend breadth53.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.43Latest activity-pressure read.
Pressure change556.7%Four-week change in activity pressure.
Leadership-17.93Latest relative-leadership reading.
RS change19.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is inexpensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 94% Model confidence 77%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength61/100Blend of value, momentum, and quality. Underlying universe rank 40; rank 1 is best.
Value83/100Relative valuation strength. Underlying universe rank 18; rank 1 is best.
Quality23/100Profitability and accounting quality. Underlying universe rank 78; rank 1 is best.
Momentum28/100Medium-term price momentum. Underlying universe rank 73; rank 1 is best.
Growth99/100Revenue and earnings growth. Underlying universe rank 2; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
6.3x
Price divided by trailing earnings.
Price / sales
66.5x
Market value relative to trailing revenue.
EV / EBITDA
5.3x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-2.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
66.1%
Gross profit retained from each unit of revenue.
Operating margin
1078.7%
Operating profit retained from revenue.
Free-cash-flow margin
-190.3%
Free cash flow generated from revenue.
Return on invested capital
16.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
281.4%
Latest one-year revenue growth.
EPS growth
763.4%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity7 / 0

7 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment56/100

Weighted news tone is neutral across 44 relevant articles.

14 positive · 29 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-28.9%Distance below the 52-week high.
13-week volatility5.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+8.0%Week of 15 May.
Worst week-12.6%Week of 12 Jun.
Latest week+0.5%Week of 31 Jul.

Shape of recent returns

Strong gains3
Modest gains11
Flat weeks0
Modest losses3
Sharp losses9
Recent vol5.3%13-week weekly-return volatility.
Base vol5.1%52-week weekly-return volatility.
Up/down split31/20Count of positive and negative weeks in the 52-week window.
Average skew3.7% / -4.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape36/100

Trend, activity pressure, participation, and risk combine to a 36/100 tape read.

 Indicator analysis17/100

Latest 12-week confirmation: trend 0/12, activity pressure 4/12, relative leadership 0/12.

Activity pressure 0.10; No reversal markers Factors48/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 56; Small Cap Core rank 36 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment56/100

Weighted news tone is neutral across 44 relevant articles.

Daxor Launches Blood Testing Lab in Eastern Kansis Insiders7 / 0

7 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202610.50 USD0.5%11.02 USD9.69 USD0.43-17.939.7KOff
24 Jul 202610.45 USD-4.1%11.15 USD9.68 USD0.41-18.036.8KOff
17 Jul 202610.90 USD3.5%11.26 USD9.67 USD0.34-16.1010.2KOff
10 Jul 202610.53 USD1.4%11.33 USD9.67 USD0.13-22.359.1KOff
3 Jul 202610.38 USD3.6%11.39 USD9.66 USD-0.10-22.2612.3KOff
26 Jun 202610.02 USD2.8%11.47 USD9.66 USD-0.19-24.5314.8KOff
19 Jun 20269.75 USD5.3%11.58 USD9.65 USD-0.30-30.077.3KOff
12 Jun 20269.26 USD-12.6%11.69 USD9.65 USD-0.35-32.1317.2KOff
5 Jun 202610.60 USD3.1%11.82 USD9.66 USD-0.34-20.824.3KOff
29 May 202610.28 USD-5.0%11.90 USD9.65 USD-0.69-26.8513.3KOff
22 May 202610.82 USD0.7%12.00 USD9.65 USD-0.86-20.928.2KOff
15 May 202610.75 USD8.0%12.10 USD9.64 USD-1.17-20.4970.0KOff
8 May 20269.95 USD-4.7%12.17 USD9.65 USD-1.48-26.6163.3KOff
1 May 202610.44 USD1.9%12.26 USD9.67 USD-1.45-18.9238.2KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.